Answers are grounded in this paper and cite their sources.
Identifies GLP-1 receptor agonist pathways in kidney disease, suggesting novel intrarenal mechanisms.
Introduction and Objective: In REMODEL, semaglutide improved endothelial cell (EC) health in adults with type 2 diabetes (T2D) and chronic kidney disease (KD), but intrarenal mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RA) are unclear. We identified intrarenal genes and pathways responsive to GLP-1RA use in KD. Methods: scRNA-seq analysis was done in kidney biopsy tissue from 11 participants with KD (UACR ≥30 mg/g or eGFR <90 mL/min/1.73m2; Fig A). Genes expressed in ≥5% of cells in at least 1 major cell type were included, and ~118k cells remained after quality control (Fig B). NEBULA was used for cell type specific differential gene expression (DEG) between GLP-1RA users/non-users, followed by gene set enrichment analysis. Results: Figs D-K summarize findings in immune lymphoid, cortical thick ascending limb 2 (C-TAL-2), EC/vascular smooth muscle cells (VSMC), and immune myeloid cells, which had the highest numbers of DEGs (Fig C). Angiogenesis was enriched in immune cells, whereas hypoxia and TNFα-NFκB signaling were suppressed in immune myeloid cells. Glycolysis was enriched in EC/VSMC, whereas hypoxia and multiple metabolic pathways, including fatty acid metabolism, glycolysis, and oxidative phosphorylation, were suppressed in immune and C-TAL-2 cells. Conclusion: GLP-1RA use in early KD is associated with distinct vascular, immune, and tubular pathway signatures, extending prior observations of EC effects to the intrarenal cellular level. Disclosure Y. Choi: None. H. Hampson: None. J.D. Weissenkampen: None. J. Kanter: None. T. Vaisar: None. K. Sulek: Employee; Current; Novo Nordisk A/S. K. Bornfeldt: Advisory Panel; Current; ESPERION Therapeutics, Inc. J.A. Schaub: Consultant; Ended; Klick. D. van Raalte: Consultant; Current; AstraZeneca. Research Support; Current; AstraZeneca. Consultant; Current; Boehringer Ingelheim International GmbH. Research Support; Current; Boehringer Ingelheim International GmbH. Consultant; Current; Eli Lilly and Company. Research Support; Current; Eli Lilly and Company. Consultant; Current; Merck & Co., Inc. Research Support; Current; Merck & Co., Inc. Consultant; Current; Novo Nordisk. Research Support; Current; Novo Nordisk. K.J. Nadeau: None. S. Eddy: Research Support; Current; AstraZeneca, Eli Lilly and Company, Genentech, Inc., Sanofi, Novo Nordisk A/S, Travere Therapeutics. Other - Royalties administered through University of Michigan; Current; AstraZeneca. Research Support; Current; Certa Therapeutics, Vera Therapeutics, Dimerix. V. Nair: None. P. McCown: None. A.S. Naik: None. M.O. Alaba: None. F. Alakwaa: None. N. Nguyen: None. C. Smith: None. J.B. Hodgin: None. R. Nelson: None. K. Tuttle: Consultant; Ended; Alnylam Pharmaceuticals, Inc. Consultant; Current; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Novo Nordisk, Lilly, ProKidney. Consultant; Ended; Roche Diabetes Care. Research Support; Ended; Travere. P.E. Ladd: None. E. Zeitler: Consultant; Current; Novo Nordisk. A. Karihaloo: None. M. Kretzler: Research Support; Current; AstraZeneca, Boehringer Ingelheim International GmbH, Bayer AG, Dimerix, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., European Union, JDRF, National Institutes of Health, Novo Nordisk, Sanofi, vera therapeutics, Regeneron Pharmaceuticals Inc., Travere. P. Bjornstad: Consultant; Current; Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: